NeuroOne Medical Technologies (NASDAQ:NMTC) versus H-CYTE (OTCMKTS:HCYTD) Financial Review

NeuroOne Medical Technologies (NASDAQ:NMTC) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings & Valuation

This table compares NeuroOne Medical Technologies and H-CYTE’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$1.95 million	11.42	-$11.86 million	($0.58)	-1.38
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than NeuroOne Medical Technologies.

Analyst Ratings

This is a summary of current ratings and price targets for NeuroOne Medical Technologies and H-CYTE, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	0	0	1	0	3.00
H-CYTE	0	0	0	0	N/A

NeuroOne Medical Technologies presently has a consensus price target of $2.20, indicating a potential upside of 175.00%. Given NeuroOne Medical Technologies’ higher probable upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than H-CYTE.

Profitability

This table compares NeuroOne Medical Technologies and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-343.55%	-277.71%	-204.28%
H-CYTE	-450.40%	N/A	-777.68%

Volatility and Risk

NeuroOne Medical Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Insider and Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 5.2% of H-CYTE shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroOne Medical Technologies beats H-CYTE on 8 of the 11 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.